|First Author (Study) (Ref. #)||Sample Size and Patient Population||Study Medications||Study Design||Main Findings|
|Ruilope et al. (19)||n = 1,328 with hypertension||LCZ696 100, 200, and 400 mg vs. valsartan 80, 160, and 320 mg vs. AHU377 200 mg||Randomized controlled dose-ranging study; primary endpoint was reduction in BP between groups at 8 weeks||Significant reductions in systolic and diastolic BPs with LCZ696 200 mg vs. valsartan 160 mg and with LCZ696 400 mg vs. valsartan 320 mg; significant reduction in ambulatory BP with LCZ vs. valsartan|
|Kario et al. (20)||n = 309 Asians with hypertension||LCZ696 100, 200, and 400 mg vs. placebo||Randomized controlled dose-ranging study||Significant reductions in systolic and diastolic BPs, pulse pressure, and ambulatory pressure with LCZ696|
|Solomon et al. (PARAMOUNT) (22)||n = 301 with HFpEF||LCZ696 200 mg bid vs. valsartan 160 mg bid||Randomized controlled trial; primary endpoint was reduction in NT-proBNP at 12 weeks||Significant reduction in NT-proBNP at 12 wk with LCZ696, as well as left atrial volume at 36 wk; improvement in NYHA class in patients receiving LCZ696 vs. placebo|
|McMurray et al. (PARADIGM-HF) (26)||n = 8,442 with HFrEF||LCZ696 200 mg bid vs. enalapril 10 mg bid||Randomized controlled trial; primary outcome was cardiovascular death or HF hospitalization||Significant reductions in the primary outcome (20%), cardiovascular death (20%), and all-cause mortality (16%) with LCZ696 vs. enalapril|
bid = twice daily; BP = blood pressure; HF = heart failure; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; NT-proBNP = N-terminal pro–brain (or B-type) natriuretic peptide; NYHA = New York Heart Association; PARADIGM-HF = Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure; PARAMOUNT = Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction.